Become A Featured Company

DNA Genetics’ Charles Phillips Talks Cannabis Branding with CFN Media

Ash Stringer

August 5th, 2019

App, Exclusive, News, Top Story

As the cannabis market moves from the back alley to the boardroom, we are gaining an increasing appreciation for the role genetics play in developing distinct varieties with unique medical and commercial application. As the cannabis market matures, the significance of genetic selection is quickly becoming a focus of the discussion. Cannabis has been loosely regulated in its’ infancy, and the impact of genetics has yet to be fully understood. Companies are now realizing the pivotal role genetics play in producing consistent and quality cannabis.

Cannabis is distinctive, the genetics of each specific strain create a wide-ranging effect all its own. These strains can be similar in many respects, but no two strains are entirely alike. The wide-ranging effects could leave a person lethargic one day and energized the next. This guessing game is not what consumers, dispensaries or regulators want. 

It’s All About The Brand

Many companies in the cannabis industry have yet to establish a brand distinguishing themselves from competitors. Branding serves many purposes including, developing confidence with consumers and building trust that a brand will consistently deliver quality products. This is especially important when you are dealing with psychoactive chemicals like the ones found in the cannabis plant. Each molecule of the plant can create different and varied effects in individuals, based on the genetics of the strain. Flagship brands are highlighting the key role of genetics, when defining a particular strain’s effects, ensuring that the effect is consistent and repeatable.

Click here to receive an Investor Presentation and Company Updates

“The reason that we’re a brand is because we think that is where the safety and authenticity lies for the consumer,” said Charles Phillips, CEO of DNA Genetics, a premier provider of genetics to the cannabis industry. In a recent interview with CFN Media’s Nova Gavers, Phillips states, “From a consumer standpoint, anytime you see “Powered by DNA” on that logo, you’re pretty much going to be understanding that it’s the equivalent of seeing ‘Intel Inside.’ That’s a big deal.”

 

 

Charles Phillips, CEO of DNA Genetics, a premier provider of cannabis genetics, believes that the industry still has a long road ahead of them to improve standardized methods of processing.

During the interview with CFN Media, Phillips sheds light on the issue of cannabis patrons purchasing products based upon strains they recognize, but not taking into consideration the brands behind them. Phillips believes the cannabis industry has not placed enough importance on educating people about genetics, standardized operating procedures, and the various effects of strains. Many brands advertise to offer “the same strain” however, the intricate process to produce each strain is unique. The lack of consistency creates a result that may not meet the consumers’ expectations.

For instance, people may go into a dispensary to purchase the cannabis strain, Chocolope, without realizing that the brand is DNA Genetics. Often, the consumer receives Chocolope from another company with dissimilar genetics, resulting in an unexpected experience. DNA Genetics’ ultimate goal is to be recognized as a trusted and consistent source of quality cannabis genetics. They want consumers to rest assured they are receiving the same product with unwavering results, every time they purchase. DNA Genetics’ slogan “Powered by DNA” on the label should be an immediate recognition of quality and consistency for the consumer.

“For us, branding comes into play because we want people to know if they see DNA anywhere on that packaging, whether it be our packaging or whether it be “Powered by DNA” for someone else, you know what you’re going to get. When you are dealing with a psychoactive chemical, that is really important.” – Charles Phillips

Cannabis Passion Exemplified

DNA Genetics is one of the most well-known and regarded cannabis brands in the world. DNA was established over thirteen years ago in Amsterdam by cannabis pioneers, Don Morris and Aaron Yarkoni (“D-n-A”). At the time, it was the only market that provided a place for legal and commercial cannabis activity. Over the years, the Company has built and curated a seasoned genetic library and developed proven standard operating procedures for genetic selection, breeding, and cultivation.

They moved from their homes in California to set up a large grow facility in Amsterdam to perfect their craft before returning to expand in the burgeoning California markets.

Having spent more than a decade building their brand in the European marketplace, DNA has simultaneously been developing strategic partnerships throughout the world. DNA is poised to enter all legal markets as the laws in each territory change to provide for legal cannabis enterprises. DNA is positioned to become the first genuinely geographically-diversified Company, with multiple partnerships of top-licensed producers and brands. These producers and brands have built their companies and global presence utilizing the “Powered by DNA” model”. DNA Genetics’ intentions have not changed from the moment the company was created. Their passion for the genetics of cannabis and commitment to quality has been unwavering.

Click here to receive an Investor Presentation and Company Updates

Don Morris and Aaron Yarkoni, co-founders of DNA Genetics have been recognized for their many contributions to the cannabis industry. They were named as part of High Times’ 100 Most Influential People in Cannabis. They were also awarded the High Times Trail Blazers Award for contributions made towards uniting the fields of entrepreneurship, politics and medicine. The brand has been considered a genetics powerhouse with best-in-class cultivars for over a decade. DNA Genetics has amassed more than 200 global cannabis awards during the course of their career.

Their vision and work have not only earned them industry accolades, but also a partnership with Canopy Growth Corp. (NYSE: CGC) (TSX: WEED), the largest cannabis company in the world. In 2015, the two companies partnered to collaborate and develop world-class cannabis for their first agreement in the Canadian market. DNA provided Canopy with unique and genetically-diverse strains that were incorporated into Canopy’s Canadian product lines.

In March 2017, the partnership between Canopy Growth and DNA was renewed and expanded, into Jamaica, Germany, and other international markets. Under the terms of the announcement, Canopy Growth and DNA committed to working together through 2024. They will continue to make every effort to expand into global markets, including Europe, where regulations permit the legal sale of cannabis for medical and recreational purpose.

Charles Phillips, CEO of DNA Genetics, explains that DNA is only interested in working with top notch companies that share the same commitment to quality. Only teaming with fully vetted partners to share in revenue streams, the company can ensure it expands globally in a responsible and efficient manner. He emphasizes that shareholders are investing in heritage and legacy companies, with highly efficient capital expenditure models and a knowledgeable management team like DNA Genetics.

Phillips states, “From an investor standpoint, it is really helpful because you know we are going to work with vetted partners and we are going to be partnering with them in terms of revenue recognition and licensing revenue. That is pretty easily supported by what we are telling them. You have another signifier to verify the forecast we are giving you. More importantly, it is really an efficient use of capital.”

Charles Phillips and the “DNA Army” place great importance on the industry foundation being built upon informative discussions about cannabis and how it affects people. He believes education is the key component to achieving a successful, safe, and well-rounded industry.

Click here to receive an Investor Presentation and Company Updates

For Additional Information on DNA Genetics please visit the website at dnagenetics.com

The above article is sponsored content.

Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer.

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ash Stringer

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading